MedTrace Logo

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

NCT00750802 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2009-06-26

No results posted yet for this study

Summary

The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD6280

10mg Capsule, oral, single-dose

DRUG

AZD6280

40mg Capsule, oral, single-dose

DRUG

Lorazepam

2mg tablet, oral single-dose

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Completion
2008-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750802 on ClinicalTrials.gov